Evaluating VB15010 Tablets for Advanced Solid Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety, tolerability, and anti-cancer activity of VB15010, a PARP1 inhibitor, in patients with advanced solid tumors. The study includes patients with confirmed advanced malignancies who have progressive cancer and specific genetic mutations related to homologous recombination repair. Participants will receive the experimental treatment and be monitored for its effects and side effects. The trial is designed to gather data that could inform future treatment options for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 at the time of screening;
* Histological or cytological confirmation of advanced malignancy ;
* Progressive cancer at the time of study entry;
* Adequate organ and marrow function as defined by the protocol;
* Homologous recombination repair gene mutation.

Exclusion Criteria:

* Major surgery within 4 weeks of the first dose of study treatment.
* Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \>10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.
* Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).

Where it's running

• Cancer Hospital of Shandong First Medical university
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Song Jia Project manager, bachelor
• Email: songjia@vybio.com
• Phone: China 86+18503817651

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing HS-10502 for advanced solid tumors

  This study is testing a new drug called HS-10502 to see if it can help people with advanced solid tumors that have certain genetic mutations and who haven't had success with standard treatments.

  Recruiting Phase 1 Jiangsu Hansoh Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT05740956

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers

  This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07552467

• Adherence to a Remote Physical Activity Program on a Smartwatch and its Effect on Fatigue After Adjuvant Chemotherapy

  This study tests whether sticking with an adapted physical activity program tracked on a smartwatch can reduce fatigue in adults who have finished adjuvant chemotherapy for certain cancers.

  Recruiting Centre Antoine Lacassagne · Nice · NCT07429487

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Evaluating zanidatamab for HER2-expressing tumors

  This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.

  Recruiting at 30 sites Phase 2 Jazz Pharmaceuticals · Prescott, Arizona and 41 other locations · NCT06695845

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.